Tag Archives: Myriad

Patenting Genes – The Conversation Myriad Needs To Start

Posted on April 5, 2010 by Warren Woessner

I watched “60 Minutes” last night, during which Kevin Noonan got about 30 seconds to justify “patenting genes” and the Myriad BRAC1-2 assays. He did as well as could be done, speaking about the good the patent system does in … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

BIO Press Release

Posted on March 31, 2010 by Warren Woessner

For Immediate Release   www.bio.org  Contact: Stephanie Fischer     (202) 312-9263 or sfischer@bio.org BIO Statement on Initial Decision in Myriad Genetics Lawsuit Washington, D.C. (March 30, 2010) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Myriad Ruling: DNA Sequences Are Unpatentable “ Products Of Nature”

Posted on March 30, 2010 by Warren Woessner

In a lengthy opinion released yesterday in Assoc. for Molec. Pathology v. USPTO, __F.Supp.2d___(S.D. N.Y.) (PDF below), the court invalidated claims directed to isolated DNA sequences, as well as to cancer screening methods using them, and even to methods of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | 1 Comment

Warren Woessner Participates In Virtual Debate With Chris Hansen On The Myriad Lawsuit

Posted on August 17, 2009 by Warren Woessner

Cameron MacKendrick sponsors podcasts on issues of interest in IP law. In this one, I am trying to explain the debate surrounding both the patentability of “natural products” as well as the patentability of diagnostic assays and their relationship t … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | Leave a comment